Assessment of Myostatin as Biomarker of Frailty in Chronic Kidney Disease Patients in Babylon Governorate

Abstract

Frailty is characterized by irregularities of several systems, which result in a reduction of physiologic storage, an impairment of dynamic homeostasis, and an increased susceptibility to morbidity and death in the aftermath. Furthermore, frailty is a typical occurrence in people with chronic kidney disease (CKD) and increases with the progression of kidney diseases. Myostatin is mostly generated in the skeletal muscles in reaction to a number of substances, such as glucocorticoids, ammonia, angiotensin II, oxidative stress, as well as cytokines associated with inflammation. Skeletal muscle hypertrophy and hyperplasia are caused by myostatin gene elimination. To determine if myostatin is a useful biomarker for detecting frailty in patients with CKD. This research conducted a case–control study involving a total of 90 participants, with 45 individuals diagnosed with CKD and 45 apparently healthy individuals serving as the control group. Blood samples were collected to measure myostatin and albumin. Other variables, including age and body mass index, were also assessed. Statistical analyses, including receiver operating characteristic (ROC)-curve analysis, were conducted to evaluate the diagnostic accuracy of FGF23. The current study found a significant increase in the concentration of myostatin with the control group at a P value significant ( P < 0.05), also the result of MSTN ROC the percent of the area under the curve was 94.3%. The results emphasize that myostatin plays a crucial role in CKD.